In last trading session, Dyne Therapeutics Inc (NASDAQ:DYN) saw 1.24 million shares changing hands with its beta currently measuring 1.10. Company’s recent per share price level of $13.82 trading at $0.04 or 0.29% at ring of the bell on the day assigns it a market valuation of $1.41B. That closing price of DYN’s stock is at a discount of -243.34% from its 52-week high price of $47.45 and is indicating a premium of 5.43% from its 52-week low price of $13.07.
For Dyne Therapeutics Inc (DYN), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.25. Splitting up the data highlights that, out of 8 analysts covering the stock, 0 rated the stock as a Sell while 1 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 7 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.91 in the current quarter.
Dyne Therapeutics Inc (NASDAQ:DYN) trade information
Upright in the green during last session for gaining 0.29%, in the last five days DYN remained trading in the green while hitting it’s week-highest on Friday, 02/14/25 when the stock touched $13.82 price level, adding 4.69% to its value on the day. Dyne Therapeutics Inc’s shares saw a change of -41.34% in year-to-date performance and have moved 2.22% in past 5-day. Dyne Therapeutics Inc (NASDAQ:DYN) showed a performance of -2.19% in past 30-days.
Wall Street analysts have assigned a consensus price target of 45 to the stock, which implies a rise of 69.29% to its current value. Analysts have been projecting 18 as a low price target for the stock while placing it at a high target of 55. It follows that stock’s current price would drop -30.25% in reaching the projected high whereas dropping to the targeted low would mean a loss of -30.25% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -106.26% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 12.26% while estimates for its earnings growth in next 5 years are of 1.02%.
Dyne Therapeutics Inc (NASDAQ:DYN)’s Major holders
BLACKROCK INC. is the top institutional holder at DYN for having 7.39 million shares of worth $260.69 million. And as of 2024-06-30, it was holding 9.1148 of the company’s outstanding shares.
The second largest institutional holder is ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC, which was holding about 8.02 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.6697 of outstanding shares, having a total worth of $283.03 million.
